The shortages of abatacept (Orencia®) subcutaneous products in Australia will be resolved from 1 July 2022.

Bristol Myers Squibb Australia is pleased to advise that the Orencia (abatacept) subcutaneous (SC) presentations shortage has been resolved. What this means is:

• The Serious Scarcity Substitution Instrument (SSSI) and the TGA shortage notification for the SC preparations of Orencia is no longer in place
• The Orencia Stock Hypercare Plan (OSHP) has ceased and normal prescribing and ordering processes for all Orencia presentations has resumed
• Patients may switch back to, and new patients may be initiated on, any of the Orencia presentations (IV or SC) as deemed appropriate by their treating physician

Stock of the intravenous (IV) abatacept Orencia presentation has also recently improved and new patients can be started on this medicine.

 

Consumers should contact their rheumatologists for further advice.